Table 1 Patient demographics and laboratory findingsa
From: Rosiglitazone as an option for patients with acromegaly: a case series
3 months | 6 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Patient | Sex | Age, years | Previous treatment | GH normal range, ng/ml | Basal GH level, ng/ml | Nadir GH level, ng/ml | IGF-1 level, ng/ml (normal value for age) | GH level, ng/ml | IGF-1 level, ng/ml | GH level, ng/ml | IGF-1 level, ng/ml |
1 | Woman | 57 | S, R, O | 0.003 to 0.97 | 10.0 | 4.32 | 990 (80 to 197) | 3.26 | 400 | 1.24 | 284 |
2 | Man | 51 | S, O | 0.010 to 3.60 | 12 | 4.01 | 1016 (80 to 157) | 20.73 | 1700 | 9.39 | 540 |
3 | Woman | 32 | S, R, O | 0.003 to 0.97 | 47 | 29.9 | 1640 (98 to 226) | 11.1 | 715 | 4.29 | 635 |
4 | Man | 36 | S, O | 0.010 to 3.60 | 84 | 71 | 2400 (98 to 226) | 51 | 2850 | 11 | 375 |